MAP2K7 and melanoma: Studies have shown that BRAF-targeted kinase inhibitors are effective for patients with BRAF gene mutations (Zaman et al., 2019), and the combined use of BRAF and MEK inhibitors has been approved for the treatment of advanced melanoma patients with BRAF V600e mutations (Kakadia et al., 2018).